Articles tagged "Kidney transplantation"

2016 American Transplant Congress
Urinary Markers of Proximal Tubular Dysfunction in Kidney Transplant as Predictors for CKD.
P. Garcia, V. Garcia-Nieto, J. Navarro, E. Martin, A. Rivero, A. Jarque, J. Gonzalez-Posadas, M. Macia.
Nephrology, Universitary NTRA.SRA.Candelaria Hospital, SC Tenerife, Spain.
AIMS:Analyze urinary markers of proximal tubular dysfunction (PTD)(b2 microglobulin (b2m),N-acetyl-glucosaminidase (NAG) and Clara Cell Protein (CC16)) in kidney transplant (KT) patients, compared with a healthy…
2016 American Transplant Congress
The Impact of Non-Adherence on Disparities in African-American Kidney Transplant Recipients.
D. Taber, A. Chokkalingam, A. Posadas, R. Browning, N. Salazar, M. Kamel, R. Pullalarevu, B. Kadri, T. Srinivas, K. Chavin, P. Baliga.
MUSC, Charleston, SC.
Background: Non-adherence is considered to a be a strong risk factor for graft loss in kidney transplant recipients, with conflicting evidence of its impact on…
2016 American Transplant Congress
Rapid Discontinuation of Prednisone (RDP) in Kidney Transplant (KTx) Recipients: 15-Year Outcomes.
O. Serrano,¹ R. Kandaswamy,¹ K. Gillingham,¹ W. Payne,¹ T. Dunn,¹ S. Chinnakotla,¹ E. Finger,¹ H. Ibrahim,² A. Kukla,² R. Spong,² N. Issa,² T. Pruett,¹ A. Matas.¹
¹Surgery, University of Minnesota, Minneapolis, MN; ²Medicine, University of Minnesota, Minneapolis, MN.
PURPOSE: RDP after KTx is associated with increased early rejection; no decrease in medium‐term patient (PS) or graft survival (GS); and significantly decreased prednisone‐related side…
2016 American Transplant Congress
Benefit of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation with 2 Years Follow-Up.
Y. Watarai,¹ M. Okada,¹ K. Futamura,¹ T. Nagai,¹ T. Yamamoto,¹ M. Tsujita,¹ T. Hiramitsu,¹ N. Goto,¹ S. Narumi,¹ T. Kobayashi.²
¹Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan; ²Kidney Transplant Surgery, Aichi Medical University, Nagoya, Aichi, Japan.
Purpose: Prospective randomized study of MMF addition to everolimus (EVR) based immunosuppression in order to further reduction of EVR and CNI was evaluated in clinical…
2016 American Transplant Congress
Outcomes of Deceased Donor Kidney Transplantation from Diabetic Donors: Does Presence of Recipient Diabetes Matter?
J. Rogers,¹ A. Farney,¹ G. Orlando,¹ A. Reeves-Daniel,² A. Palanisamy,² H. El-Hennawy,¹ M. Khan,¹ M. Gautreaux,¹ S. Iskandar,³ W. Doares,⁴ S. Kaczmorski,⁴ R. Stratta.¹
¹Surgery, Wake Forest Baptist Medical Center, Winston-Salem, NC; ²Internal Medicine, WFBMC, Winston-Salem, NC; ³Pathology, WFBMC, Winston-Salem, NC; ⁴Pharmacy, WFBMC, Winston-Salem, NC.
Donor history of diabetes mellitus (DM) is a known risk factor for inferior graft survival after deceased donor kidney transplantation (DDKT) and is heavily weighted…
2016 American Transplant Congress
Steroid Use May Not Increase Risk of Fracture in Kidney Transplant Patients.
N. Sarabu, K. Kucharski, D. Hricik, A. Padiyar, A. Huml, J. Augustine.
Internal Medicine, Division of Nephrology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH.
Introduction: Chronic steroid use is associated with bone mineral loss, and osteoporosis. However, it is not clear if chronic steroid use in post-kidney transplant patients…
2016 American Transplant Congress
Preformed Antibodies Against AT₁R and EDNRA Correlate with Rejection Post-Transplant.
A. Gareau,¹ C. Wiebe,^1,2 D. Pochinco,² I. Gibson,³ D. Rush,¹ P. Nickerson.^1,2,4
¹Internal Medicine, University of Manitoba, Winnipeg, MB, Canada; ²Diagnostic Services of Manitoba, Winnipeg, MB, Canada; ³Pathology, University of Manitoba, Winnipeg, MB, Canada; ⁴Immunology, University of Manitoba, Winnipeg, MB, Canada.
Studies have investigated the potential pathogenic effects of non-HLA antibodies (Ab), with a few reporting that Ab against the angiotensin II type 1 receptor (AT1R)…
2016 American Transplant Congress
Alemtuzumab Induction Allows Better Rejection Free Graft Survival in Comparison to Basiliximab Although with Increased Post Transplant Viral Infections.
V. Siddagangaiah,¹ H. Sharma,² N. Lal,¹ J. Rai,¹ M. Howse,¹ D. Ridgway,¹ A. Sharma,¹ A. Hammad,¹ S. Mehra.¹
¹Renal Transplant Surgery, Royal Liverpool and Broadgreen University Hospital, Liverpool, United Kingdom; ²Transplant Surgery, Manchester Royal Infirmary, Manchester, United Kingdom.
Introduction: 3C study concluded that in comparison to basiliximab, alemtuzumab induction reduces the risk of biopsy proven acute rejection (BPAR) in renal transplant recipients. In…
2016 American Transplant Congress
Immunosuppressive Actions of CLI95 and CORM401 on TLR4 in Renal Ischemia Reperfusion Injury.
P. Luke,^1,2,5 G. Cepinskas,^1,4 H. Alharbi,^3,5 A. Haig,^3,5 R. Bhattacharjee.^1,2,5
¹Matthew Mailing Centre, London Health Sciences Centre, London, Canada; ²Surgery, Western University, London, Canada; ³Pathology and Laboratory Medicine, Western University, London, Canada.
Background: Kidneys from all donor sources are highly sensitive to ischemia-reperfusion injury (IRI). However, grafts donated after cardiac death (DCD) sustain an increased incidence of…
2016 American Transplant Congress
Altruistic Kidney Donation: From the Donor's Perspetive.
R. Burge,¹ S. Potts,^2,3 S. Lundie.⁴
¹Edinburgh Medical School, University of Edinburgh, Edinburgh, United Kingdom; ²Department of Psychological Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom; ³Department of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom; ⁴Transplant Unit, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
Introduction: Although all living kidney donors are offered yearly reviews post-transplant, the restricted contact time and medical focus limits understanding of the motivations and experiences…